Regional citrate anticoagulation with 4% sodium citrate

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The choice of the method of anticoagulation during various extracorporeal procedures is relevant in view of the increasing frequency of the use of this procedure by doctors of various specialties. Regional citrate anticoagulation (RCA) has a number of advantages over systemic anticoagulation with heparin, including: longer filter life in renal replacement therapy (RRT), lower risk of bleeding. In order to achieve maximum efficiency and safety of RCA, many different citrate dosing algorithms have been proposed; protocol citrate anticoagulation with 4% sodium citrate is the most studied. This literature review discusses the main studies evaluating the efficacy and safety of this technique. Currently, research results allow professional communities to recommend CAR as the method of choice for extended RRT.

Full Text

Restricted Access

About the authors

Erik A. Avetisyan

National Medical Research Center of Cardiology n.a. Acad. E.I. Chazov

Author for correspondence.
Email: nataliakostritsaffm@gmail.com
ORCID iD: 0000-0002-9660-9851

Cardiologist at the Intensive Care Unit of the Department of Emergency Cardiology, National Medical Research Center of Cardiology n.a. Acad. E.I. Chazov

Russian Federation, Moscow

Natalya S. Kostritsa

National Medical Research Center of Cardiology n.a. Acad. E.I. Chazov

Email: nataliakostritsaffm@gmail.com
ORCID iD: 0000-0002-8746-8727

Cardiologist, Resident at the Intensive Care Unit of the Department of Emergency Cardiology, National Medical Research Center of Cardiology n.a. Acad. E.I. Chazov

Russian Federation, Moscow

References

  1. Deepa. C., Muralidhar K. Renal replacement therapy in ICU. J. Anaesthesiol. Clin. Pharmacol. 2012;28:386.
  2. Christopher W.M., James O.B. Dialysis. BMJ. 2014;348:bmj.g2–bmj.g2.
  3. Brandenburger T., Dimski T., Slowinski T., Kindgen-Milles D. Renal replacement therapy and anticoagulation. Best Pract. Res. Clin. Anaesthesiol. 2017;31:387–401.
  4. Schetz M. Anticoagulation in Continuous Renal Replacement Therapy. Eds. C. Ronco, R. Bellomo, G. La Greca. Contribut. Nephrol. 2001;132:283–303.
  5. Singh S. Anticoagulation during Renal Replacement Therapy. Indian J. Crit. Care Med. 2020;24:112–16.
  6. Frías A., et al. Efectividad de anticoagulación regional con citrato en terapia de reemplazo renal continua. Rev. Méd. Chile. 2022;150:283–88.
  7. Lenga I., Hopman W.M., O’Connell A.J., et al. Flexitrate regional citrate anticoagulation in continuous venovenous hemodiafiltration: a retrospective analysis. BMC. Nephrol. 2019;20:452.
  8. Buccione E., et al. Regional Citrate Anticoagulation and Systemic Anticoagulation during Pediatric Continuous Renal Replacement Therapy: A Systematic Literature Review. J. Clin. Med. 2022;11:3121.
  9. Rhee H., Berenger B., Mehta R.L., Macedo E. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study. Am. J. Kidney Dis. 2021;78:550–9.e1.
  10. Poh C.B., et al. Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy – A Safe and Effective Low‐Dose Protocol. Nephrol. 2020;25:305–13.
  11. Kindgen-Milles D., Brandenburger T., Dimski T. Regional citrate anticoagulation for continuous renal replacement therapy: Curr. Opin. Crit. Care. 2018;24:450–54.
  12. Kellum J.A., Lameire N. For the KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part. 1). Crit. Care 2013;17:204.
  13. Shum H.-P., Kwan A.M.-C., Chan K.-C., Yan W.-W. The Use of Regional Citrate Anticoagulation Continuous Venovenous Hemofiltration in Extracorporeal Membrane Oxygenation. ASAIO J. 2014;60:413–18.
  14. Rajsic S., et al. Anticoagulation Strategies during Extracorporeal Membrane Oxygenation: A Narrative Review. J. Clin. Med. 2022;11:5147.
  15. Brogan T.V., Lequier L., Lorusso R. et al. Extracorporeal life support: the ELSO red book. 2017.
  16. Hosgood S.A., et al. Normothermic machine perfusion versus static cold storage in donation after circulatory death kidney transplantation: a randomized controlled trial. Nat. Med. 2023 doi: 10.1038/s41591-023-02376-7.
  17. Oudemans-van Straaten H.M., Ostermann M. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Crit. Care 2012;16: 249.
  18. Fisher R., et al. Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study. Ann. Intensive Care. 2022;12:29.
  19. Burry L.D., et al. Regional Citrate Anticoagulation for PrismaFlex Continuous Renal Replacement Therapy. Ann. Pharmacother. 2009;43:1419–25.
  20. Morgera S., et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit. Care Med. 2009;37:2018–24.
  21. .Joannidis M. Regional citrate anticoagulation – Finally on its way to standardization? Crit. Care Med. 2009;37:2128–29.
  22. Arepally G.M. Heparin-induced thrombocytopenia. Blood. 2017;129:2864–72.
  23. Wiegele M., et al. Thrombin Generation and Platelet Function in ICU Patients Undergoing CVVHD Using Regional Citrate Anticoagulation. Front. Med. 2021;8:680540.
  24. Tang X., et al. Application of regional citrate anticoagulation in patients at high risk of bleeding during intermittent hemodialysis: a prospective multicenter randomized controlled trial. J. Zhejiang Univ.-Sci. 2022;23:931–42.
  25. Zhang W., et al. Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: A systematic review and meta‐analysis. Semin. Dial. 2021;34:196–208.
  26. Zarbock A., et al. Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy on Dialysis Filter Life Span and Mortality Among Critically Ill Patients With Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2020;324:1629.
  27. Stucker F., et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit. Care 2015;19:91.
  28. Feng X., Deng L., Zhang Y., Chang L. Regional citrate versus heparin anticoagulation in continuous renal replacement therapy in critically ill patients: a Meta-analysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:982–87.
  29. Liu C., Mao Z., Kang H., Hu J., Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit. Care. 2016;20:144.
  30. Cointault O., et al. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol. Dial. Transplant. 2004;19:171–78.
  31. Morgera S., et al. Metabolic Complications during Regional Citrate Anticoagulation in Continuous Venovenous Hemodialysis: Single-Center Experience. Nephron Clin. Pract. 2004;97:131–36.
  32. Bai M., et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intens. Care Med. 2015;41:2098–110.
  33. Fernández S.N., et al. Citrate Anticoagulation for CRRT in Children: Comparison with Heparin. BioMed Res. Int. 2014;2014:1–7.
  34. Kramer L., et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients: Crit. Care Med. 2003;31:2450–55.
  35. Persic V., et al. Regional citrate anticoagulation for continuous renal replacement therapy in newborns and infants: Focus on citrate accumulation. Artif. Organs. 2020;44:497–503.
  36. Bakker A.J., Boerma E.C., Keidel H., et al. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. Clin. Chem. Lab. Med. 2006;CCLM:44.
  37. Rhee H., Berenger B., Mehta R.L., Macedo E. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study. Am. J. Kidney Dis. 2021;78: 550–9.e1.
  38. Khadzhynov D., et al. Efficacy and complications of regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients with COVID-19. J. Crit. Care. 2022;67:126–31.
  39. Botan E., et al. Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation in Children with Liver Dysfunction/Failure. J. Trop. Pediatr. 2022;68:fmac048.
  40. Hu F., Sun Y., Bai K., Liu C. Clinical application of regional citrate anticoagulation for continuous renal replacement therapy in children with liver injury. Front. Pediatr. 2022;10:847443.
  41. Schultheiß C., et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit. Care. 2012;16:R162.
  42. Peng B., Lu J., Guo H., et al. Regional citrate anticoagulation for replacement therapy in patients with liver failure: A systematic review and meta-analysis. Front. Nutr. 2023;10:1031796.
  43. Saner F.H., et al. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol. Dial. Transplant. 2012;27:1651–57.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies